Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake

被引:65
作者
Hutchings, Martin
Loft, Annika
Hansen, Mads
Ralfkiaer, Elisabeth
Specht, Lena
机构
[1] Copenhagen Univ Hosp, Rigshosp, Dept Clin Physiol & Nucl Med, PET & Cyclotron Unit, Copenhagen, Denmark
[2] Copenhagen Univ Hosp, Rigshosp, Dept Haematol, Copenhagen, Denmark
[3] Copenhagen Univ Hosp, Rigshosp, Dept Pathol, Copenhagen, Denmark
[4] Copenhagen Univ Hosp, Rigshosp, Dept Oncol, Copenhagen, Denmark
[5] Copenhagen Univ Hosp, Rigshosp, Dept Radiotherapy, Copenhagen, Denmark
关键词
Hodgkin lymphoma; PET/CT; FDG; histopathology;
D O I
10.1002/hon.782
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) enables quantitative analysis of metabolic activity. This study investigated standardized uptake value (SUV) levels in the different histopathological subtypes of Hodgkin lymphoma (HL). Sixty patients with newly diagnosed HL underwent staging FDG-PET/CT after lymph node biopsy. Maximum SUV in each patient (SUVmax/total) and in each affected region or organ (SUVmax) were recorded. Mean SUVmax/total was 9.3 g/ml in seven nodular lymphocyte predominance (NLP) patients, 16.3 g/ml in 38 nodular sclerosis (NS) patients, 20.8 g/ml in 11 mixed cellularity (MC) patients, and 19.5 g/ml in four patients with unclassified classical HL (CHL-NOS), (ANOVA, p = 0.011). Out of 780 sites (600 lymph node regions plus 180 organs), 208 sites were found to be affected with HL. Mean SUVmax was 8.3 g/ml in the 12 sites with NLP, 11.2 g/ml in the 147 sites affected with NS, 14.6 g/ml in the 36 sites with MC, and 13.1 g/ml in the 13 sites with CHL-NOS (ANOVA, p = 0.002). There is a significant difference in FDG/glucose uptake between the different histopathological subtypes of HL. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:146 / 150
页数:5
相关论文
共 30 条
[1]   Comparison between 2-deoxy-2-[18F]fluoro-D-Glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma [J].
Allen-Auerbach, M ;
Quon, A ;
Weber, WA ;
Obrzut, S ;
Crawford, T ;
Silverman, DHS ;
Ratib, O ;
Phelps, ME ;
Czernin, J .
MOLECULAR IMAGING AND BIOLOGY, 2004, 6 (06) :411-416
[2]  
[Anonymous], 1999, HODGKINS DIS
[3]   Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDC-PET) for accurate staging of Hodgkin's disease [J].
Bangerter, M ;
Moog, F ;
Buchmann, I ;
Kotzerke, J ;
Griesshammer, M ;
Hafner, M ;
Elsner, K ;
Frickhofen, N ;
Reske, SN ;
Bergmann, L .
ANNALS OF ONCOLOGY, 1998, 9 (10) :1117-1122
[4]   Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer [J].
Bradley, J ;
Thorstad, WL ;
Mutic, S ;
Miller, TR ;
Dehdashti, F ;
Siegel, BA ;
Bosch, W ;
Bertrand, RJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01) :78-86
[5]   Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume [J].
Brianzoni, E ;
Rossi, G ;
Ancidei, S ;
Berbellini, A ;
Capoccetti, F ;
Cidda, C ;
D'Avenia, P ;
Fattori, S ;
Montini, GC ;
Valentini, G ;
Proietti, A .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (12) :1392-1399
[6]   The role of positron emission tomography in radiation treatment planning [J].
Bujenovic, S .
SEMINARS IN NUCLEAR MEDICINE, 2004, 34 (04) :293-299
[7]   Positron emission tomography in patients with Hodgkin's disease:: Correlation to histopathologic subtypes [J].
Döbert, N ;
Menzel, C ;
Berner, U ;
Hamscho, N ;
Wördehoff, N ;
Mitrou, P ;
Grünwald, F .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (04) :565-571
[8]   Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? [J].
Girinsky, T ;
Pichenot, C ;
Beaudre, A ;
Ghalibafian, M ;
Lefkopoulos, D .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (01) :218-226
[9]   Intensity-modulated radiotherapy for lymphoma involving the mediastinum [J].
Goodman, KA ;
Toner, S ;
Hunt, M ;
Wu, EJ ;
Yahalom, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (01) :198-206
[10]  
Hueltenschmidt B, 2001, CANCER-AM CANCER SOC, V91, P302, DOI 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO